case_images: PMC11300210_01
case_images: Histopathologic stains from thymic (A-J). (A) hematoxylin and eosin(400X); (B) showed the thymic tumor cells were cytoplasmic positive for CD5/6 (200X); (C) showed the thymic tumor cells were cytoplasmic positive for P63 (400X); (D) showed the thymic tumor cells were cytoplasmic positive for CD117 (400X); (E) showed the thymic tumor cells were cytoplasmic positive for CD5(400X); (F) showed the thymic tumor cells were cytoplasmic negative TTF1(400X); (G) showed the thymic tumor cells were cytoplasmic positive forLCA(400X); (H) showed the thymic tumor cells were cytoplasmic negative TdT(400X); (I) showed the thymic tumor cells were cytoplasmic negative NapsinA(200X); (J) showed the thymic tumor cells were cytoplasmic negative CK7 (400X).
case_images: fonc-14-1326006-g001.jpg
case_images: PMC11300210_01_fonc-14-1326006-g001.jpg
case_images: f1
case_images: TdT (-) ( Figure 1 ), indicating squamous cell carcinoma.
case_images: PD-L1 expression TPS negative, TPS<1% (TPS<1%); PD-L1 expression CPS positive, CPS>=1(CPS=1).
case_images: fonc-14-1326006-g002.jpg
case_images: PMC11300210_01_fonc-14-1326006-g002.jpg
case_images: f2
case_images: The PD-L1 expression level was that the tumor proportion score (TPS) was found to be less than 1%, and the combine positive score (CPS) was found to be 1% ( Figure 2 ).
case_images: Time line of treatments of the patient and changes in CT scan of thymic carcinoma during treatments Chest computed tomography (CT) revealed a clearly reduced the size of anterior mediastinum lesion indic- ated by red arrows, with a maximum diameter decreasing from 99 mm to 52 mm.
case_images: fonc-14-1326006-g003.jpg
case_images: PMC11300210_01_fonc-14-1326006-g003.jpg
case_images: f3
case_images: Chest computed tomography (CT) revealed a clearly reduced the size of anterior mediastinum lesion, with a maximum diameter decreasing from 99 mm to 52 mm ( Figure 3 ).
case_images: Biochemical and hematological changes after immunotherapy. Reference range:fT4 (8.7-17.3 pmol/L), fT3(2.8-7.1pmol/L), TSH(0.27-4.2uIU/ml), CRO(172-497nmol/L), GLU(3.9- 6.1mmol/L), HGB(115-15 0g/L), PLT(100-300*10^9/L), WBC(3.5-9.5*10^9/L), NEUT(1.8-6.3*10^9/ L), CK(26-140U/ L), CK-MB (0-24 U/L), LDH(140-271U/L).
case_images: fonc-14-1326006-g004.jpg
case_images: PMC11300210_01_fonc-14-1326006-g004.jpg
case_images: f4
case_images: No severe side effects appeared during immunotherapy for 17 months ( Figure 4 ).